This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Genocea Biosciences Balance Sheet Health
Financial Health criteria checks 3/6
Key information
61.7%
Debt to equity ratio
US$7.65m
Debt
| Interest coverage ratio | n/a |
| Cash | US$20.14m |
| Equity | US$12.39m |
| Total liabilities | US$26.40m |
| Total assets | US$38.79m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GBI1's short term assets ($24.4M) exceed its short term liabilities ($18.0M).
Long Term Liabilities: GBI1's short term assets ($24.4M) exceed its long term liabilities ($8.4M).
Debt to Equity History and Analysis
Debt Level: GBI1 has more cash than its total debt.
Reducing Debt: GBI1's debt to equity ratio has increased from 51.9% to 61.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GBI1 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GBI1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 0.2% each year